AbilityPharma is a phase 2b biopharma company developing first-in-class oral targeted drugs inducing cytotoxic autophagy selectively in cancer cells. Completed Phase 2b trial in pancreatic cancer with a defined treatment effect. Completed Phase 2a data in lung and endometrial cancer.